The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans.

The role that in vitro systems can play in toxicological risk assessment is determined by the appropriateness of the chosen methods, with respect to the way in which in vitro data can be extrapolated to the in vivo situation. This report presents the results of a workshop aimed at better defining the use of in vitro-derived biomarkers of toxicity (BoT) and determining the place these data can have in human risk assessment. As a result, a conceptual framework is presented for the incorporation of in vitro-derived toxicity data into the risk assessment process. The selection of BoT takes into account that they need to distinguish adverse and adaptive changes in cells. The framework defines the place of in vitro systems in the context of data on exposure, structural and physico-chemical properties, and toxicodynamic and biokinetic modeling. It outlines the determination of a proper point-of-departure (PoD) for in vitro-in vivo extrapolation, allowing implementation in risk assessment procedures. A BoT will need to take into account both the dynamics and the kinetics of the compound in the in vitro systems. For the implementation of the proposed framework it will be necessary to collect and collate data from existing literature and new in vitro test systems, as well as to categorize biomarkers of toxicity and their relation to pathways-of-toxicity. Moreover, data selection and integration need to be driven by their usefulness in a quantitative in vitro-in vivo extrapolation (QIVIVE).

[1]  Sebastian Hoffmann,et al.  Integrated Testing Strategy (ITS) - Opportunities to better use existing data and guide future testing in toxicology. , 2010, ALTEX.

[2]  Thomas Hartung,et al.  Food for Thought ... on mapping the human toxome. , 2011, ALTEX.

[3]  M. Leist,et al.  Neuroprotection by Minocycline Caused by Direct and Specific Scavenging of Peroxynitrite* , 2010, The Journal of Biological Chemistry.

[4]  W. Slob,et al.  Toxicodynamic analysis of the inhibition of isolated human acetylcholinesterase by combinations of methamidophos and methomyl in vitro. , 2009, Toxicology and applied pharmacology.

[5]  George Loizou,et al.  Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[6]  J. Hermens,et al.  Influence of albumin on sorption kinetics in solid-phase microextraction: consequences for chemical analyses and uptake processes. , 2007, Analytical chemistry.

[7]  Harvey J Clewell,et al.  A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. , 2001, Environmental health perspectives.

[8]  R Kroes,et al.  Application of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients. , 2007, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[9]  Martin van den Berg,et al.  Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[10]  Melvin E Andersen,et al.  Toxicity Testing in the 21st Century: Implications for Human Health Risk Assessment , 2009, Risk analysis : an official publication of the Society for Risk Analysis.

[11]  D J Paustenbach,et al.  Adjusting exposure limits for long and short exposure periods using a physiological pharmacokinetic model. , 1987, American Industrial Hygiene Association journal.

[12]  D. Lauffenburger,et al.  Physicochemical modelling of cell signalling pathways , 2006, Nature Cell Biology.

[13]  Steven K. Gibb.  Toxicity testing in the 21st century: a vision and a strategy. , 2008, Reproductive toxicology.

[14]  Cameron Mackay,et al.  Assuring Consumer Safety without Animal Testing: A Feasibility Case Study for Skin Sensitisation , 2008, Alternatives to laboratory animals : ATLA.

[15]  Jeppe Falsig,et al.  Progressive Degeneration of Human Mesencephalic Neuron-Derived Cells Triggered by Dopamine-Dependent Oxidative Stress Is Dependent on the Mixed-Lineage Kinase Pathway , 2005, The Journal of Neuroscience.

[16]  Silke Gabbert,et al.  Towards optimization of chemical testing under REACH: a Bayesian network approach to Integrated Testing Strategies. , 2010, Regulatory toxicology and pharmacology : RTP.

[17]  J. Bailar,et al.  Toxicity Testing in the 21st Century: A Vision and a Strategy , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[18]  A J Ryan,et al.  Development of a 3D human in vitro skin co‐culture model for detecting irritants in real‐time , 2010, Biotechnology and bioengineering.

[19]  K. Boekelheide,et al.  SOT/EUROTOX debate: biomarkers from blood and urine will replace traditional histopathological evaluation to determine adverse responses. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[20]  Jan G Hengstler,et al.  Compound selection for in vitro modeling of developmental neurotoxicity. , 2012, Frontiers in bioscience.

[21]  Alicia Paini,et al.  A physiologically based biodynamic (PBBD) model for estragole DNA binding in rat liver based on in vitro kinetic data and estragole DNA adduct formation in primary hepatocytes. , 2010, Toxicology and applied pharmacology.

[22]  H Seibert,et al.  Factors influencing nominal effective concentrations of chemical compounds in vitro: medium protein concentration. , 2002, Toxicology in vitro : an international journal published in association with BIBRA.

[23]  Hasso Seibert,et al.  In vitro-in vivo extrapolation: estimation of human serum concentrations of chemicals equivalent to cytotoxic concentrations in vitro. , 2003, Toxicology.

[24]  Thomas Hartung,et al.  From alternative methods to a new toxicology. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[25]  Karl-Heinz Krause,et al.  The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy. , 2008, ALTEX.

[26]  Melvin E. Andersen,et al.  Toxicity Testing in the 21st Century: Defining New Risk Assessment Approaches Based on Perturbation of Intracellular Toxicity Pathways , 2011, PloS one.

[27]  Mardas Daneshian,et al.  The Center for Alternatives to Animal Testing - Europe (CAAT-EU): a transatlantic bridge for the paradigm shift in toxicology. , 2010, ALTEX.

[28]  Albert P. Li,et al.  Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: results with model toxicants aflatoxin B1, cyclophosphamide and tamoxifen. , 2012, Chemico-biological interactions.

[29]  Ruili Huang,et al.  Quantitative high-throughput screening for chemical toxicity in a population-based in vitro model. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  Marcel Leist,et al.  Evaluation of Developmental Toxicants and Signaling Pathways in a Functional Test Based on the Migration of Human Neural Crest Cells , 2012, Environmental health perspectives.

[31]  Valérie Zuang,et al.  Report of the EPAA–ECVAM Workshop on the Validation of Integrated Testing Strategies (ITS) , 2012, Alternatives to laboratory animals : ATLA.

[32]  P. Bushnell,et al.  Developing an exposure-dose-response model for the acute neurotoxicity of organic solvents: overview and progress on in vitro models and dosimetry. , 2005, Environmental toxicology and pharmacology.

[33]  Tanja Waldmann,et al.  Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome. , 2012, Human molecular genetics.

[34]  Development of a negligible depletion-solid phase microextraction method to determine the free concentration of chlorpromazine in aqueous samples containing albumin. , 2011, Journal of chromatography. A.

[35]  Marcel Leist,et al.  TLR2 Hypersensitivity of Astrocytes as Functional Consequence of Previous Inflammatory Episodes , 2011, The Journal of Immunology.

[36]  Michael Balls,et al.  Integrated Testing Strategies for Toxicity Employing New and Existing Technologies , 2011, Alternatives to laboratory animals : ATLA.

[37]  A. Wobus,et al.  Present state and future perspectives of using pluripotent stem cells in toxicology research , 2011, Archives of Toxicology.

[38]  Silke Gabbert,et al.  Quo vadis integrated testing strategies? Experiences and observations from the work floor , 2012 .

[39]  E. Maser,et al.  Cytotoxic potency of H2O2 in cell cultures: impact of cell concentration and exposure time. , 2010, Free radical biology & medicine.

[40]  Kannan Krishnan,et al.  Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms , 2012, Journal of toxicology.

[41]  Thomas Hartung.  Food for thought... on evidence-based toxicology. , 2009, ALTEX.

[42]  Robert M. Bruce,et al.  Assessment of the Oral Rat Chronic Lowest Observed Adverse Effect Level Model in TOPKAT, a QSAR Software Package for Toxicity Prediction , 2004, J. Chem. Inf. Model..

[43]  Thomas Hartung,et al.  Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare. , 2012, ALTEX.

[44]  P. Olinga,et al.  Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[45]  Valérie Zuang,et al.  Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010 , 2011, Archives of Toxicology.

[46]  Justin G. Teeguarden,et al.  Benchmark calculations from summarized data: an example , 2007, Environmental and Ecological Statistics.

[47]  Patricia Ruiz,et al.  SAR/QSAR methods in public health practice. , 2011, Toxicology and applied pharmacology.

[48]  Wolfgang Link,et al.  High content screening: seeing is believing. , 2010, Trends in biotechnology.

[49]  Eric Leclerc,et al.  The Current Status of Alternatives to Animal Testing and Predictive Toxicology Methods Using Liver Microfluidic Biochips , 2011, Annals of Biomedical Engineering.

[50]  Jeffrey M. Perkel.  LIFE SCIENCE TECHNOLOGIES: Animal-Free Toxicology: Sometimes, in Vitro is Better , 2012 .

[51]  Marcel Leist,et al.  Assessment of chemical-induced impairment of human neurite outgrowth by multiparametric live cell imaging in high-density cultures. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[52]  J. J. van de Sandt,et al.  Decrease of intracellular pH as possible mechanism of embryotoxicity of glycol ether alkoxyacetic acid metabolites. , 2010, Toxicology and applied pharmacology.

[53]  Hasso Seibert,et al.  Impact of protein binding on the availability and cytotoxic potency of organochlorine pesticides and chlorophenols in vitro. , 2002, Toxicology.

[54]  Bas J Blaauboer,et al.  The contribution of in vitro toxicity data in hazard and risk assessment: current limitations and future perspectives. , 2008, Toxicology letters.

[55]  Bas J Blaauboer,et al.  On the incorporation of chemical-specific information in risk assessment. , 2008, Toxicology letters.

[56]  Hasso Seibert,et al.  Validation of a prediction model for estimating serum concentrations of chemicals which are equivalent to toxic concentrations in vitro. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[57]  J. Pennings,et al.  Application of toxicogenomics in hepatic systems toxicology for risk assessment: acetaminophen as a case study. , 2011, Toxicology and applied pharmacology.

[58]  Hasso Seibert,et al.  In Vitro-In Vivo Extrapolation of Toxic Potencies for Hazard and Risk Assessment - Problems and New Developments , 2006 .

[59]  A G Renwick,et al.  Human variability and noncancer risk assessment--an analysis of the default uncertainty factor. , 1998, Regulatory toxicology and pharmacology : RTP.

[60]  Mardas Daneshian,et al.  A framework program for the teaching of alternative methods (replacement, reduction, refinement) to animal experimentation. , 2011, ALTEX.

[61]  L. Gribaldo,et al.  Report of the International Workshop on In Vitro Methods for Assessing Acute Systemic Toxicity , 2000 .

[62]  M. Leist,et al.  Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells. , 2009, Toxicology and applied pharmacology.

[63]  H. Schlüter,et al.  Identification of Thalidomide-Specific Transcriptomics and Proteomics Signatures during Differentiation of Human Embryonic Stem Cells , 2012, PloS one.

[64]  Bas J Blaauboer,et al.  Biokinetic Modeling and in Vitro–in Vivo Extrapolations , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[65]  Wytse J. Wadman,et al.  Health Council of the Netherlands: No need to change from SAR to time-temperature relation in electromagnetic fields exposure limits , 2011, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[66]  Joop L. M. Hermens,et al.  Solid phase microextraction as a tool to determine membrane/water partition coefficients and bioavailable concentrations in in vitro systems. , 1997, Chemical research in toxicology.

[67]  Marcel Leist,et al.  Food for thought ... considerations and guidelines for basic test method descriptions in toxicology. , 2010, ALTEX.

[68]  Elisabeth Verpoorte,et al.  Microfluidic biochip for the perifusion of precision‐cut rat liver slices for metabolism and toxicology studies , 2010, Biotechnology and bioengineering.

[69]  H Seibert,et al.  Factors influencing nominal effective concentrations of chemical compounds in vitro: cell concentration. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.

[70]  A. Boyles,et al.  National Institute of Environmental Health Sciences , 2008 .

[71]  Thomas Hartung,et al.  The dawning of a new age of toxicology. , 2008, ALTEX.

[72]  T W Schultz,et al.  Using chemical categories to fill data gaps in hazard assessment , 2009, SAR and QSAR in environmental research.

[73]  David M. Reif,et al.  Aggregating Data for Computational Toxicology Applications: The U.S. Environmental Protection Agency (EPA) Aggregated Computational Toxicology Resource (ACToR) System , 2012, International journal of molecular sciences.

[74]  W. Lindner,et al.  Drug-protein binding sites. New trends in analytical and experimental methodology. , 1996, Journal of chromatography. B, Biomedical applications.

[75]  Melvin E. Andersen,et al.  The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative , 2006, Archives of Toxicology.

[76]  Andreas Luch,et al.  Wind of Change Challenges Toxicological Regulators , 2012, Environmental health perspectives.

[77]  A. J. Gandolfi,et al.  Precision-cut tissue chips as an in vitro toxicology system. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[78]  Petra S Kern,et al.  Integrating non-animal test information into an adaptive testing strategy - skin sensitization proof of concept case. , 2011, ALTEX.

[79]  M Balls,et al.  Methods of in vitro toxicology. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[80]  Valérie Zuang,et al.  ECVAM and new technologies for toxicity testing. , 2012, Advances in experimental medicine and biology.

[81]  Anna Forsby,et al.  Integration of in vitro neurotoxicity data with biokinetic modelling for the estimation of in vivo neurotoxicity , 2007, Human & experimental toxicology.

[82]  Bas J Blaauboer,et al.  Evaluation of research activities and research needs to increase the impact and applicability of alternative testing strategies in risk assessment practice. , 2011, Regulatory toxicology and pharmacology : RTP.

[83]  Manuel J T Carrondo,et al.  Merging bioreactor technology with 3D hepatocyte-fibroblast culturing approaches: Improved in vitro models for toxicological applications. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[84]  Thomas B Knudsen,et al.  Zebrafish: as an integrative model for twenty-first century toxicity testing. , 2011, Birth defects research. Part C, Embryo today : reviews.

[85]  Ralph Kühne,et al.  Quantitative read-across for predicting the acute fish toxicity of organic compounds. , 2011, Environmental science & technology.

[86]  Bas J Blaauboer,et al.  Quantifying processes determining the free concentration of phenanthrene in Basal cytotoxicity assays. , 2012, Chemical research in toxicology.

[87]  Robert J Kavlock,et al.  Incorporating biological, chemical, and toxicological knowledge into predictive models of toxicity. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[88]  Daniel L Villeneuve,et al.  Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment , 2010, Environmental toxicology and chemistry.

[89]  Melvin E Andersen,et al.  Defining and modeling known adverse outcome pathways: Domoic acid and neuronal signaling as a case study , 2011, Environmental toxicology and chemistry.

[90]  Christian Beste,et al.  Translating neurobehavioural endpoints of developmental neurotoxicity tests into in vitro assays and readouts. , 2012, Neurotoxicology.

[91]  T. Knudsen,et al.  A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing. , 2012, ALTEX.

[92]  J. DeJongh,et al.  Estimation of systemic toxicity of acrylamide by integration of in vitro toxicity data with kinetic simulations. , 1999, Toxicology and applied pharmacology.

[93]  Carol A Marchant,et al.  In Silico Tools for Sharing Data and Knowledge on Toxicity and Metabolism: Derek for Windows, Meteor, and Vitic , 2008, Toxicology mechanisms and methods.

[94]  Mark T D Cronin,et al.  A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity , 2011, Expert opinion on drug metabolism & toxicology.

[95]  Melvin E Andersen,et al.  A mechanistic redefinition of adverse effects - a key step in the toxicity testing paradigm shift. , 2010, ALTEX.

[96]  Maxime Culot,et al.  New strategy for alerting central nervous system toxicity: Integration of blood-brain barrier toxicity and permeability in neurotoxicity assessment. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[97]  E. Mariman,et al.  Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[98]  Kristin Schirmer,et al.  Development of a partition-controlled dosing system for cell assays. , 2010, Chemical research in toxicology.

[99]  A. Henn,et al.  Characterization of mouse cell line IMA 2.1 as a potential model system to study astrocyte functions. , 2012, ALTEX.

[100]  W. Russell,et al.  Ethical and Scientific Considerations Regarding Animal Testing and Research , 2011, PloS one.

[101]  H Marquart,et al.  Use of read-across and tiered exposure assessment in risk assessment under REACH--a case study on a phase-in substance. , 2010, Regulatory toxicology and pharmacology : RTP.

[102]  Michael Balls,et al.  Biomarkers as Predictive Tools in Toxicity Testing , 2000 .

[103]  J B Houston,et al.  The Integrated Use of Alternative Methods in Toxicological Risk Evaluation , 1999, Alternatives to laboratory animals : ATLA.

[104]  W. Koh,et al.  Coordinated waves of gene expression during neuronal differentiation of embryonic stem cells as basis for novel approaches to developmental neurotoxicity testing , 2011, Cell Death and Differentiation.

[105]  Jeppe Falsig,et al.  Defined inflammatory states in astrocyte cultures: correlation with susceptibility towards CD95‐driven apoptosis , 2003, Journal of neurochemistry.

[106]  Marcel Leist,et al.  Metabolic Depletion of Atp by Fructose Inversely Controls Cd95- and Tumor Necrosis Factor Receptor 1–Mediated Hepatic Apoptosis , 2000, The Journal of experimental medicine.

[107]  R. Judson,et al.  Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. , 2011, Chemical research in toxicology.

[109]  Harvey J Clewell,et al.  Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results , 2012, Critical reviews in toxicology.

[110]  Marcel Leist,et al.  The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. , 2009, ALTEX.

[111]  Leonora Buzanska,et al.  Developmental neurotoxicity testing: recommendations for developing alternative methods for the screening and prioritization of chemicals. , 2011, ALTEX.

[112]  Tanja Waldmann,et al.  Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing. , 2010, ALTEX.

[113]  M. Leist,et al.  Uncoupling of ATP-depletion and cell death in human dopaminergic neurons. , 2012, Neurotoxicology.

[114]  Andrew Worth,et al.  Metabolism: A Bottleneck in In Vitro Toxicological Test Development , 2006, Alternatives to laboratory animals : ATLA.

[115]  Robert J Kavlock,et al.  Predictive models of prenatal developmental toxicity from ToxCast high-throughput screening data. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[116]  Minne B Heringa,et al.  Toward more useful in vitro toxicity data with measured free concentrations. , 2004, Environmental science & technology.

[117]  Salomon Sand,et al.  The point of transition on the dose‐effect curve as a reference point in the evaluation of in vitro toxicity data , 2012, Journal of applied toxicology : JAT.

[118]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.